3.13
2.78 (787.19%)
2.78 (787.19%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 157,986 |
|
|||||
| News | - | ||||||
| Day High | 3.49 | Low High |
|||||
| Day Low | 2.86 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 2.78 | 787.19% | 3.13 | 19:39:09 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.46 | 2.86 | 3.49 | 3.117 | 0.3528 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,008 | 157,986 | $ 3.09 | $ 488,817 | - | 2.20 - 6.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:55:16 | 75 | $ 3.03 | USD |
Period:
Draw Mode:
Marker Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 261.67M | 83.60M | 58.84M | $ 1.24M | $ - | -0.56 | -0.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 21.30% |
Marker Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.012 | 4.3645 | 2.86 | 3.80 | 531,269 | 0.118 | 3.92% |
| 1 Month | 2.40 | 4.3645 | 2.311 | 3.45 | 364,900 | 0.73 | 30.42% |
| 3 Months | 4.235 | 4.47 | 2.20 | 3.21 | 311,873 | -1.11 | -26.09% |
| 6 Months | 3.221 | 6.60 | 2.20 | 4.71 | 1,123,860 | -0.091 | -2.83% |
| 1 Year | 6.10 | 6.70 | 2.20 | 4.57 | 758,248 | -2.97 | -48.69% |
| 3 Years | 29.60 | 37.70 | 2.20 | 17.18 | 872,734 | -26.47 | -89.43% |
| 5 Years | 100.10 | 102.50 | 2.20 | 23.01 | 723,806 | -96.97 | -96.87% |
Marker Therapeutics Description
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |